Double Autologous Stem Cell Transplantation in a Case of Non-secretory Multiple Myeloma

Erzsébet Lázár; Marius Găzdac; Szende Jakab; István Benedek; Judit-Beáta Köpeczi; Annamária Pakucs; János Ács; István Benedek

doi:10.1515/jim-2016-0058

.blurhash-client-img { display: none !important; }

Double Autologous Stem Cell Transplantation in a Case of Non-secretory Multiple Myeloma

Journal of Interdisciplinary Medicine

Volume 1 (2016): Issue 3 (December 2016)

By: Erzsébet Lázár, Marius Găzdac, Szende Jakab, István Benedek, Judit-Beáta Köpeczi, Annamária Pakucs, János Ács and István Benedek

Open Access

|Dec 2016

Abstract

Multiple myeloma represents a challenge for hematologists because it has become more frequent at a young age in recent years. This is why autologous stem cell transplantation is included in the standard treatment of myeloma patients. We present the case of a 39-year-old patient who was diagnosed with non-secretory myeloma with double autologous transplantation and underwent neurosurgery for spinal cord compression caused by a plasmocytoma at D5 level. We present the evolution and complexity of this very difficult case.

References

1. Attal M, Harouseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide imporves survival in patinets with multiple myeloma. Blood. 2006;108:3289-3294.10.1182/blood-2006-05-022962
Search in Google Scholar Back to article
2. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high dose chemotherapy for multiple myeloma: Final results of a phase III US intergroup trail S9321. J Clin Oncol. 2006;24:929-936.10.1200/JCO.2005.04.5807
Search in Google Scholar Back to article
3. van Rhee F, Giralt S, Barlogie B. The future of autologous stem cell transplantation in myeloma. Blood. 2014;124:328-333.10.1182/blood-2014-03-561985
Search in Google Scholar Back to article
4. Koreth J, Clutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma. A systematic review and meta-analysis of randomised controlled trials. Biol Blood Marrow Transplant. 2007;13:183-196.10.1016/j.bbmt.2006.09.010
Search in Google Scholar Back to article
5. Kroger N, Perez-Simon J, Myint H, et al. Influence of timing allogenic stem cell transplantation after dose-redused melphalan/fludarabine condition in multiple myeloma. Biol Blood and Marrow Transplant. 2004;10:698-708.10.1016/j.bbmt.2003.12.098
Search in Google Scholar Back to article
6. Moreau P, San Miguel J, Ludwig H. Multiple Myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl6):vi133-137.10.1093/annonc/mdt297
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.1515/jim-2016-0058 | Journal eISSN: 2501-8132 | Journal ISSN: 2501-5974

Journal RSS Feed

Language: English

Page range: 297 - 299

Submitted on: Nov 2, 2016

Accepted on: Nov 10, 2016

Published on: Dec 30, 2016

Published by: Asociatia Transilvana de Terapie Transvasculara si Transplant KARDIOMED

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

multiple myeloma,

plasmocitoma,

autologous transplantation

Related subjects:

Medicine,

Clinical medicine,

Clinical medicine, other,

Internal medicine,

Internal medicine, other,

Emergency medicine and intensive-care medicine,

Surgery,

Surgery, other

© 2016 Erzsébet Lázár, Marius Găzdac, Szende Jakab, István Benedek, Judit-Beáta Köpeczi, Annamária Pakucs, János Ács, István Benedek, published by Asociatia Transilvana de Terapie Transvasculara si Transplant KARDIOMED
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 1 (2016): Issue 3 (December 2016)